SHP2 Inhibitor Signal pathway: RAS、I/OView More

 

JAB-3068 is the second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).

As date of Mar 22, 2023
  • U.S.
  • China
  • Global

JAB-3312


Therapy Indications Phase I Phase IIa Recent progress
KRAS G12Ci Combination Therapy KRAS G12C mut NSCLC
 
 
 
Phase IIa initiated
Jul 2022
Combo w/EGFRi Osimertinib progressed NSCLC
 
 
 
FPI
Jan 2022
Combo w/PD-1 mAb NSCLC, HNSCC, ESCC
 
 
 
Phase IIa FPI
Feb 2022
Mono BRAF Class 3/NF1 LOF mutant solid tumors
 
 
 
Closed to enrollment

 

JAB-3068


Therapy Indications Phase I Phase IIa Recent progress
Mono ESCC, HNSCC, NSCLC, ACC
 
 
 
Closed to enrollment
Combo w/PD-1 mAb ESCC, HNSCC, NSCLC
 
 
 
 

KRAS G12C Inhibitor Signal pathway: RASView More

Glecirasib

Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.

As date of Mar 22, 2023
  • U.S.
  • China
  • Global

Glecirasib

Therapy Indications Phase I Phase IIa Pivotal Recent progress
Mono NSCLC
 
 
 
Pivotal study FPI
Sep 2022
BTD granted
Dec 2022
Mono CRC, PDAC and other solid tumors
 
 
 
  Phase IIa FPI
Mar 2022
Mono NSCLC, CRC
 
 
 
  Phase II does expansion Initiated
Sep 2022
Mono 1L NSCLC with STK11 co-mutation
 
 
 
  FPI in China
Sep 2022
Combo w/SHP2i JAB-3312 NSCLC, CRC and other solid tumors
 
 
 
  FPI
May 2022
Combo w/EGFR mAb CRC
 
 
 
  FPI
Feb 2023
Combo w/PD-1 mAb NSCLC
 
 
 
   

BET Inhibitor Signal pathway: MYC View More

JAB-8263

JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have shown that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.

As date of Mar 22, 2023
  • U.S.
  • China
  • Global

JAB-8263

Therapy Indications IND Phase I Phase II Recent progress
Monotherapy Solid Tumor
 
 
 
 
Monotherapy Solid Tumor
 
 
 
FPI
Feb 2022
Monotherapy MF, AML
 
 
 
FPI
Apr 2021

Aurora A inhibitor Signal pathway: RBView More

JAB-2485

JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.

As date of Mar 22, 2023
  • U.S.
  • China
  • Global

JAB-2485

Therapy Indications IND Phase I Phase II Recent progress
Monotherapy Solid Tumor
 
 
 
IND Approved in China
Oct 2022
FPI in U.S.
Jan 2023

CD73 monoclonal antibody Signal pathway: I/OView More

JAB-BX102

JAB-BX102 is a humanized anti-CD73 monoclonal antibody (mAb)developed by Jacobio to inhibit the enzymatic activity of CD73. CD73 is the key node of adenosine pathway, and its inhibitors have broad therapeutic prospects for tumors dependent on adenosine pathway. Relevant studies have shown that adenosine promotes SHP2 phosphorylation, suggesting that anti-CD73 antibody can be combined with SHP2 inhibitor, which is also developed by Jacobio to benefit patients with advanced solid tumors.

As date of Mar 22, 2023
  • U.S.
  • China
  • Global

JAB-BX102

Therapy Indications IND Phase I Phase IIa Recent progress
Mono and Combo w/ PD-1 antibody Solid Tumor
 
 
 
FPI in China
Sep 2022

GUE inhibitorSignal pathway: Tumor metabolism

JAB-24114

JAB-24114 is Jacobio’s self-developed GUE (glutamine-utilizing enzyme) inhibitor. Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors.

As date of Mar 17, 2023
  • U.S.
  • China
  • Global

JAB-24114

Therapy Indications IND Phase I Phase IIa Recent progress
Monotherapy Solid Tumor
 
 
 
IND Approved in China
Mar 2023

LIF monoclonal antibodySignal pathway: RAS

JAB-BX300

JAB-BX300 is Jacobio’s self-developed LIF mAb. LIF is an important biomarker in pancreatic ductal adenocarcinoma (PDAC). Studies show that, LIF plays a crucial role in KRAS-driven cancer models and the blockade of LIF by antibodies represents an attractive approach to improving therapeutic outcomes. LIF is an attractive target for the treatment of KRAS-driven tumors, which has potential to combo with KRAS and SHP2 inhibitors.

As date of Apr 4, 2023
  • U.S.
  • China
  • Global

JAB-BX300

Therapy Indications IND Phase I Phase IIa Recent progress
Monotherapy Solid Tumor
 
 
 
IND Approved in China
Apr 2023

IND-enabling Stage Candidates

 

Asset Target Modality IND Schedule Indications Recent Development Lead Optimization IND-enabling
JAB-26766 PARP7
(I/O)
Small molecule 2023 IND Solid tumors Candidate nominated, entering into IND
enabling studies in Jan 2022
 
 
JAB-23400 KRASmulti
(RAS pathway)
Small molecule 2023 IND PDAC, CRC, NSCLC Candidate nominated, entering into IND-enabling studies in 2022
 
 
JAB-30300 P53 Y220C
(P53 pathway)
Small molecule 2023 IND Solid tumors Candidate nominated, entering into IND
enabling studies in Jul 2022
 
 
JAB-BX400 HER2-STING
(I/O)
iADC - Solid tumors -
 
 
JAB-X1800 CD73-STING
(I/O)
iADC 2024 IND Solid tumors Candidate nominated in 2023 Q1
 
 
JAB-22000 KRAS G12D
(RAS pathway)
Small molecule 2024 IND PDAC, CRC, NSCLC -
 
 

Abbreviation: mAb = monoclonal antibody; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non-small cell lung cancer; KRAS amp = KRAS amplification; LOF = loss of function; CRC = colorectal cancer; MF = myelofibrosis; AML = acute myeloid leukemia; CRPC = castration resistant prostate cancer; HCC = hepatocellular carcinoma; PDAC = pancreatic ductal adenocarcinoma; IND = investigational new drug.

As date of Apr 4, 2023